Abstract
This study reports that B-chronic lymphocytic leukemia (B-CLL) cells display the same pattern of toll-like receptors (TLRs) proteins expression as normal B-cells, yet with overexpression of TLR9. Furthermore, TLR7 and TLR9 appear to be functional and liable to respond to specific ligands, respectively imidazoquinolines and CpG-ODN thus potentially opening new therapeutic approaches.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Apoptosis
-
Cell Proliferation
-
Flow Cytometry
-
Gene Expression Regulation
-
Humans
-
Imidazoles / pharmacology
-
Immunophenotyping
-
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
-
Leukemia, Lymphocytic, Chronic, B-Cell / metabolism*
-
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
-
Oligodeoxyribonucleotides / pharmacology
-
Quinolines / pharmacology
-
Receptors, TNF-Related Apoptosis-Inducing Ligand
-
Toll-Like Receptor 9 / metabolism
-
Toll-Like Receptors / metabolism*
Substances
-
CPG-oligonucleotide
-
Imidazoles
-
Oligodeoxyribonucleotides
-
Quinolines
-
Receptors, TNF-Related Apoptosis-Inducing Ligand
-
Toll-Like Receptor 9
-
Toll-Like Receptors